| Identification | More | [Name]
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride | [CAS]
63074-08-8 | [Synonyms]
1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-[(TETRAHYDRO-2-FURANYL)CARBONXYL]PIPERAZINE, HYDROCHLORIDE
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine
1-[4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL]-4-([TETRAHYDRO-2-FURANYL]CARBONYL) PIPERAZINE HYDROCHLORIDE
[4-(4-AMINO-6,7-DIMETHOXY-QUINAZOLIN-2-YL)PIPERAZIN-1-YL]-OXOLAN-2-YL-METHANONE
HYTRIN
TERAZOSIN
TERAZOSIN HCL
TERAZOSIN HYDROCHLORIDE
TERAZOSIN MONOHYDROCHLORIDE
abbott-45975
piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)c
Tetrachlorphthalsureanhydrid
s-(+-2-alaninol)
Terazosin monohydrochloride anhydrous
Terazosin hydrochloride anhydride
Tetrazosin hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride
2-[4-(Tetrahydro-2-furoyl)-piperazine]-4-amino-6,7-dimethoxyquinazoline-hydrochloride
Dysalfa
Flotrin | [Molecular Formula]
C19H26ClN5O4 | [MDL Number]
MFCD00467965 | [Molecular Weight]
423.89 | [MOL File]
63074-08-8.mol |
| Chemical Properties | Back Directory | [Melting point ]
261-263°C | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
H2O: 25 mg/mL
| [form ]
powder
| [color ]
white to off-white
| [Water Solubility ]
Soluble in water at 20mg/ml. Also soluble in methanol or ethanol. | [Stability:]
Stable for 2 years as supplied. Solutions in distilled water may be stored at -20° for up to 3 months. | [InChI]
InChI=1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H | [InChIKey]
IWSWDOUXSCRCKW-UHFFFAOYSA-N | [SMILES]
NC1=NC(N2CCN(C(C3OCCC3)=O)CC2)=NC2=CC(OC)=C(OC)C=C12.Cl | [CAS DataBase Reference]
63074-08-8(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,Xi | [Risk Statements ]
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [RTECS ]
TK8044925
| [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral |
| Hazard Information | Back Directory | [Description]
Terazosin hydrochloride is a highly water-soluble antihypertensive agent with a
structure and profile closely related to that of prazosin. | [Originator]
Abbott (USA) | [Uses]
Hytrin (Abbott). | [Brand name]
Terazosin
is INN and BAN;HEITRIN. | [General Description]
Terazosin hydrochloride, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride (Hytrin), is a structuralcongener of prazosin hydrochloride. It possessessimilar selective properties of specifically inhibiting 1-adrenergic receptors. The drug is slightly less potent thanprazosin hydrochloride. Terazosin hydrochloride has a halflifeof approximately 12 hours, which is much longer thanthat of prazosin. This lends itself to a once-daily dose tocontrol hypertension in many patients. | [Biological Activity]
α 1 - and α 2B -adrenoceptor antagonist (K i values are 3.3, 0.7, 1.1, 7.7, 1510 and 78.2 nM for α 1A , α 1B , α 1D , α 2B , α 2A and α 2C receptors respectively). Antihypertensive following oral or intravenous administration in vivo . | [Biochem/physiol Actions]
α1-adrenoceptor antagonist. | [storage]
Store at RT | [References]
References/Citations
1) Hancock et al. (1995), Actions of terazosin and its enantiomers at subtypes of alpha-1 and alpha-2 adrenoceptors in vitro; Recept. Signal Transduct. Res., 15 863
2) Kyncl et al. (1986), Pharmacology of terazosin; Am. J. Med., 80 12
3) Shionoiri et al. (1994), Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study; Am. J. Med. Sci., 307 Suppl 1 S91
4) Pan et al. (2003), Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells; J. Urol., 169 724
5) Chen et al. (2015), Terazosin activates Pgk1 and HSP90 to promote stress resistance; Nat. Chem. Biol., 11 19 |
|
|